IDH1 Inhibitor 9, identified by its CAS number 3037967-71-5, is a small molecule designed to inhibit the activity of the isocitrate dehydrogenase 1 (IDH1) enzyme, which plays a crucial role in cellular metabolism and is implicated in various cancers, particularly gliomas and acute myeloid leukemia. This compound is characterized by its ability to selectively target mutant forms of IDH1, leading to a reduction in the production of oncometabolites such as 2-hydroxyglutarate (2-HG), which are associated with tumorigenesis. IDH1 Inhibitor 9 exhibits favorable pharmacokinetic properties, including good solubility and bioavailability, making it a promising candidate for therapeutic development. Its efficacy and safety profile are typically evaluated through preclinical and clinical studies, focusing on its potential to improve patient outcomes in IDH1-mutant cancers. As research progresses, IDH1 Inhibitor 9 may contribute to targeted cancer therapies, highlighting the importance of precision medicine in oncology.

IDH1 Inhibitor 9

3037967-71-5: IDH1 Inhibitor 9, identified by its CAS number 3037967-71-5, is a small molecule designed to inhibit the activity of the isocitrate dehydrogenase 1 (IDH1) enzyme, which plays a crucial role in cellular metabolism and is implicated in various cancers, particularly gliomas and acute myeloid leukemia. This compound is characterized by its ability to selectively target mutant forms of IDH1, leading to a reduction in the production of oncometabolites such as 2-hydroxyglutarate (2-HG), which are associated with tumorigenesis. IDH1 Inhibitor 9 exhibits favorable pharmacokinetic properties, including good solubility and bioavailability, making it a promising candidate for therapeutic development. Its efficacy and safety profile are typically evaluated through preclinical and clinical studies, focusing on its potential to improve patient outcomes in IDH1-mutant cancers. As research progresses, IDH1 Inhibitor 9 may contribute to targeted cancer therapies, highlighting the importance of precision medicine in oncology.

<p>IDH1 Inhibitor 9 (compound 11S) (2, 4, 8, 10 µM) induces apoptosis and causes cell cycle arrest in the S phase in a dose-dependent manner.</p>

CAS 3037967-71-5

IDH1 Inhibitor 9

IDH1 Inhibitor 9

Ref: TM-T88559